Neither clinical trial includes testing the AXL inhibitor with FLT3 TKI in FLT3/ITD AML patients, despite ours and other preclinical data demonstrating that combining FLT3 and AXL inhibitors sensitizes FLT3/ITD AML cells to FLT3 TKI treatment [33, 66, 70]. This evidence concerns the gene FLT3 and acute myeloid leukemia.